HIV-1 reverse transcriptase: Role of the connection domain and RNase H in antiretroviral resistance;La transcriptase inverse du VIH-1: Rôle du domaine de connexion et de la RNase H dans la résistance aux antirétroviraux

Virologie

Volumn 14, Issue 2, 2010, Pages 129-139

  Roquebert, Bénédicte ^a   Leleu, Juliette ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Connection domain; HIV 1 reverse transcriptase; Resistance associated mutation; RNase H domain

Indexed keywords

RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DRUG SENSITIVITY; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; REVIEW; VIRUS REPLICATION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77953318163     PISSN: 12678694     EISSN: 19506961     Source Type: Journal    
DOI: 10.1684/vir.2010.0290     Document Type: Review

References (57)

1. Temin HM, Mizutani S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 1970; 226: 1211-1213
2. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-azido-3′- deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy- associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096-7100
3. Baltimore D. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 1970; 226: 1209-1211
4. Goff SP. Retroviral reverse transcriptase: synthesis, structure, and function. J Acquir Immune Defic Syndr 1990; 3: 817-831 (Pubitemid 20280610)
5. Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′- azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986; 83: 8333-8337
6. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995; 267: 988-993
7. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 1995; 2: 303-308
8. Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J, Schechter M. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol 2008; 80: 565-576 (Pubitemid 351358551)
9. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16: 138-145
10. Svicher V, Sing T, Santoro MM, et al. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 2006; 80: 7186-7198 (Pubitemid 44025215)
11. Marcelin AG, Flandre P, Furco A, et al. Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine. Antivir Ther 2006; 11: 693-699 (Pubitemid 44497164)
12. Gonzales MJ, Wu TD, Taylor J, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. Aids 2003; 17: 791-799 (Pubitemid 36547650)
13. Chandra A, Gerber T, Kaul S, Wolf C, Demirhan I, Chandra P. Serological relationship between reverse transcriptases from human T-cell lymphotropic viruses defined by monoclonal antibodies. Evidence for two forms of reverse transcriptases in the AIDS-associated virus, HTLV-III/LAV. FEBS Lett 1986; 200: 327-332
14. Smith JS, Roth MJ. Purification and characterization of an active human immunodeficiency virus type 1 RNase H domain. J Virol 1993; 67: 4037-4049 (Pubitemid 23180728)
15. Smith JS, Gritsman K, Roth MJ. Contributions of DNA polymerase subdomains to the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1994; 68: 5721-5729
16. Becerra SP, Clore GM, Gronenborn AM, et al. Purification and characterization of the RNase H domain of HIV-1 reverse transcriptase expressed in recombinant Escherichia coli. FEBS Lett 1990; 270: 76-80.
17. Davies 2nd JF, Hostomska Z, Hostomsky Z, Jordan SR, Matthews DA. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 1991; 252: 88-95.
18. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-1790
19. Bahar I, Erman B, Jernigan RL, Atilgan AR, Covell DG. Collective motions in HIV-1 reverse transcriptase: examination of flexibility and enzyme function. J Mol Biol 1999; 285: 1023-1037
20. Wohrl BM, Georgiadis MM, Telesnitsky A, Hendrickson WA, Le Grice SF. Footprint analysis of replicating murine leukemia virus reverse transcriptase. Science 1995; 267: 96-99
21. Wang J, Smerdon SJ, Jager J, et al. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc Natl Acad Sci USA 1994; 91: 7242-7246 (Pubitemid 24226839)
22. Divita G, Restle T, Goody RS. Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescence. FEBS Lett 1993; 324: 153-158 (Pubitemid 23170405)
23. Sarafianos SG, Das K, Tantillo C, et al. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA/DNA. Embo J 2001; 20: 1449-1461 (Pubitemid 32233984)
24. Hansen J, Schulze T, Mellert W, Moelling K. Identification and characterization of HIV-specific RNase H by monoclonal antibody. Embo J 1988; 7: 239-243
25. Hizi A, Hughes SH, Shaharabany M. Mutational analysis of the ribonuclease H activity of human immunodeficiency virus 1 reverse transcriptase. Virology 1990; 175: 575-580 (Pubitemid 20133461)
26. Patel PH, Jacobo-Molina A, Ding J, et al. Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase. Biochemistry 1995; 34: 5351-5363
27. Krug MS, Berger SL. Ribonuclease H activities associated with viral reverse transcriptases are endonucleases. Proc Natl Acad Sci USA 1989; 86: 3539-3543
28. Cirino NM, Cameron CE, Smith JS, et al. Divalent cation modulation of the ribonuclease functions of human immunodeficiency virus reverse transcriptase. Biochemistry 1995; 34: 9936-9943
29. Cristofaro JV, Rausch JW, Le Grice SF, DeStefano JJ. Mutations in the ribonuclease H active site of HIV-RT reveal a role for this site in stabilizing enzyme-primer-template binding. Biochemistry 2002; 41: 10968-10975
30. Gopalakrishnan V, Peliska JA, Benkovic SJ. Human immunodeficiency virus type 1 reverse transcriptase: spatial and temporal relationship between the polymerase and RNase H activities. Proc Natl Acad Sci USA 1992; 89: 10763-10767
31. Gotte M, Fackler S, Hermann T, et al. HIV-1 reverse transcriptase- associated RNase H cleaves RNA/RNA in arrested complexes: implications for the mechanism by which RNase H discriminates between RNA/RNA and RNA/DNA. Embo J 1995; 14: 833-841
32. Wisniewski M, Balakrishnan M, Palaniappan C, Fay PJ, Bambara RA. The sequential mechanism of HIV reverse transcriptase RNase H. J Biol Chem 2000; 275: 37664-37671 (Pubitemid 32004879)
33. Schultz SJ, Zhang M, Champoux JJ. Recognition of internal cleavage sites by retroviral RNases H. J Mol Biol 2004; 344: 635-652 (Pubitemid 39469209)
34. Hwang CK, Svarovskaia ES, Pathak VK. Dynamic copy choice: steady state between murine leukemia virus polymerase and polymerase-dependent RNase H activity determines frequency of in vivo template switching. Proc Natl Acad Sci USA 2001; 98: 12209-12214
35. Svarovskaia ES, Delviks KA, Hwang CK, Pathak VK. Structural determinants of murine leukemia virus reverse transcriptase that affect the frequency of template switching. J Virol 2000; 74: 7171-7178 (Pubitemid 30470703)
36. Martinez-Picado J, Martinez MA. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res 2008; 134: 104-123
37. Menendez-Arias L. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res 2008; 134: 124-146
38. Cane PA, Green H, Fearnhill E, Dunn D. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. Aids 2007; 21: 447-455 (Pubitemid 46263255)
39. Roquebert B, Flandre P, Malet I, Wirden M. Identification of a mutation (A400T) in the connection domain of the HIV-1 reverse transcriptase associated to exposure and resistance to NRTI. Los Angeles, CA, USA: CROI, 2007.
40. Waters JM, O'Neal W, White KL, et al. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. Antivir Ther 2009; 14: 231-239
41. Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. Aids 2007; 21: 215-223
42. Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW, Larder BA. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J Virol 1998; 72: 5093-5098
43. Gallego O, Corral A, de Mendoza C, Rodes B, Soriano V. Prevalence of G333D/E in naive and pretreated HIV-infected patients. AIDS Res Hum Retroviruses 2002; 18: 857-860
44. Hachiya A, Kodama EN, Sarafianos SG, et al. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2008; 82: 3261-3270 (Pubitemid 351429905)
45. Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine. J Virol 2007; 81: 7852-7859 (Pubitemid 47101471)
46. Yap SH, Sheen CW, Fahey J, et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007; 4: e335.
47. Ehteshami M, Beilhartz GL, Scarth BJ, et al. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′-deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem 2008; 283: 22222-22232
48. Hachiya A, Shimane K, Sarafianos SG, et al. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV- 1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients. Antiviral Res 2009; 82: 115-121
49. Roquebert B, Wirden M, Simon A, et al. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naive and pre-treated HIV infected patients. J Med Virol 2007; 79: 207-211 (Pubitemid 46213183)
50. Santos AF, Lengruber RB, Soares EA, et al. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS One 2008; 3: e1781.
51. Brehm JH, Mellors JW, Sluis-Cremer N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry 2008; 47: 14020-14027
52. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido- 3′-deoxythymidine resistance. Proc Natl Acad Sci USA 2007; 104: 317-322
53. Ntemgwa M, Wainberg MA, Oliveira M, et al. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob Agents Chemother 2007; 51: 3861-3869
54. Zelina S, Sheen CW, Radzio J, Mellors JW, Sluis-Cremer N. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob Agents Chemother 2008; 52: 157-163
55. Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, Pathak VK. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci USA 2005; 102: 2093-2098
56. Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J Virol 2007; 81: 6837-6845 (Pubitemid 46986620)
57. Nikolenko GN, Svarovskaia ES, Delviks KA, Pathak VK. Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency. J Virol 2004; 78: 8761-8770 (Pubitemid 39025141)